GLP-1 Receptor Agonists Significantly Cut Heart Failure Hospitalizations in HFpEF Patients, Independent of Diabetes Status
Background
Heart failure with preserved ejection fraction (HFpEF) and mildly reduced ejection fraction (HFmrEF) are complex conditions often linked to obesity and metabolic dysfunction. Current treatments struggle to address the multifaceted pathology, leaving a significant gap in improving cardiovascular outcomes. Incretin-based therapies, particularly glucagon-like peptide-1 receptor agonists (GLP-1RAs), have shown promise due to their broad cardiometabolic effects beyond glucose lowering, making them a compelling area of study for this patient population.
Study Design
This systematic review and meta-analysis searched MEDLINE and Embase through October 2025 to identify 11 studies, including randomized controlled trials (RCTs), post-hoc RCT analyses, and observational studies. The research evaluated the effects of GLP-1RAs and tirzepatide on cardiovascular outcomes in patients with HFpEF or HFmrEF. Meta-regression was employed to examine if type 2 diabetes (T2D) status modified treatment effects, while an exploratory network meta-analysis of RCTs assessed comparative efficacy across individual agents.
Results
In a meta-regression of RCTs, all P-values for interaction were > 0.05, indicating no evidence that T2D status modified the treatment effects of incretin-based therapies. Pooled RCT analyses demonstrated that these therapies significantly reduced HF hospitalization and events with a hazard ratio (HR) of 0.68 [95% confidence interval {CI} 0.52-0.88], representing a 32% reduction.
The composite outcome of cardiovascular death or HF hospitalization and/or events was also significantly reduced (HR 0.76 [95% CI 0.65-0.87]), a 24% reduction. Pooled observational data further supported these findings, showing a significant reduction in HF hospitalization and events (HR 0.60 [95% CI 0.58-0.62]), a 40% reduction. Exploratory network meta-analysis found no significant difference in efficacy between individual agents within the incretin-based therapy class.
Key Findings
- GLP-1RAs and tirzepatide reduced HF hospitalization and events by 32% (HR 0.68) in HFpEF/HFmrEF patients.
- Benefits were consistent, with no significant modification by type 2 diabetes status (all P-values for interaction > 0.05).
- Composite of cardiovascular death or HF hospitalization/events decreased by 24% (HR 0.76).
- Pooled observational data showed a 40% reduction in HF hospitalization and events (HR 0.60).
- No significant difference in efficacy was found between individual incretin-based agents.
Why It Matters
This meta-analysis provides compelling evidence that GLP-1RAs and tirzepatide offer significant cardiovascular benefits in HFpEF/HFmrEF patients, irrespective of their diabetes status. This finding expands the potential clinical application of these agents beyond glucose control, suggesting they are a crucial therapeutic option for the broader population of HFpEF patients, particularly those with obesity. For clinicians, this reinforces the rationale for prescribing GLP-1RAs in HFpEF, even in non-diabetic individuals. For biohackers and peptide users, it highlights the systemic cardiometabolic benefits of GLP-1R activation, suggesting its utility in managing complex conditions where metabolic dysfunction contributes to cardiac pathology. This moves closer to a protocol where these peptides are considered standard-of-care for HFpEF.
glp-1ra
tirzepatide
heart-failure
hfpef
hfpef
cardiovascular